Pityriasis Versicolor-A Narrative Review on the Diagnosis and Management.
Malassezia
Pitryrosporum
confocal microscopy
dermatoscopy
fungal infections
imaging
microscopy
tinea versicolor
treatment
ultraviolet radiation
yeast
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
22 Oct 2023
22 Oct 2023
Historique:
received:
20
09
2023
revised:
15
10
2023
accepted:
20
10
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
This narrative review presents a comprehensive overview of the diagnosis and management of pityriasis versicolor (PV), a common superficial fungal infection caused by the yeast Malassezia. PV is characterised by scaly hypopigmented or hyperpigmented patches, primarily affecting the upper trunk, neck, and upper arms. Regarding commensal interactions, Malassezia utilises nutrient sources without affecting the human host. In cases of pathogenicity, Malassezia can directly harm the host via virulence factors or toxins, or indirectly by triggering damaging host responses. The diagnosis typically relies on recognising characteristic clinical features. Due to the wide variability in its clinical presentation, recognising the differential diagnosis is critical. In this paper, we discuss the clinical differentials, with their dermatoscopic presentation, but also describe a range of helpful diagnostic techniques (microscopy, conventional and ultraviolet-induced fluorescence dermatoscopy, and confocal microscopy). Topical therapies are the primary treatment for PV, encompassing non-specific antifungal agents like sulphur with salicylic acid, selenium sulphide 2.5%, and zinc pyrithione. Additionally, specific topical antifungal medications with either fungicidal or fungistatic properties may also be incorporated into the topical treatment regimen, such as imidazoles, allylamines, and ciclopirox olamine. Systemic therapies might occasionally be used. Patient education and the promotion of good personal hygiene are pivotal to reduce the risk of recurrence. In recurrent cases, particularly during warmer and more humid periods, prolonged prophylaxis with topical agents should be considered.
Identifiants
pubmed: 37895478
pii: life13102097
doi: 10.3390/life13102097
pmc: PMC10608716
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
G Ital Dermatol Venereol. 1989 May;124(5):XXXIII-XXXVII
pubmed: 2620916
J Invest Dermatol. 1997 Jan;108(1):40-2
pubmed: 8980284
Front Cell Infect Microbiol. 2020 Aug 07;10:393
pubmed: 32850491
Curr Opin Infect Dis. 2006 Apr;19(2):139-47
pubmed: 16514338
Arch Dermatol. 2009 Sep;145(9):1078
pubmed: 19770464
Indian Dermatol Online J. 2021 Jun 21;13(6):822-823
pubmed: 36386743
Int J Dermatol. 2016 May;55(5):494-504
pubmed: 26710919
J Cosmet Dermatol. 2023 Feb;22(2):689-691
pubmed: 36048963
Indian J Dermatol. 2018 Sep-Oct;63(5):409-411
pubmed: 30210163
Curr Opin Microbiol. 2017 Dec;40:81-87
pubmed: 29141240
Arch Dermatol. 2002 Jan;138(1):69-73
pubmed: 11790169
Br J Dermatol. 2020 Feb;182(2):454-467
pubmed: 31077336
Glob J Health Sci. 2012 Nov 11;5(1):150-4
pubmed: 23283047
Clin Exp Dermatol. 1994 Mar;19(2):121-6
pubmed: 8050139
Indian Dermatol Online J. 2019 Nov 01;10(6):682-685
pubmed: 31807448
Pediatr Dermatol. 2023 May-Jun;40(3):578-579
pubmed: 36655624
Int J Dermatol. 2018 Jul;57(7):849-855
pubmed: 29573271
Int J Dermatol. 2022 Jan;61(1):7-19
pubmed: 34235719
Indian J Dermatol Venereol Leprol. 2000 Nov-Dec;66(6):299-300
pubmed: 20877107
Dermatol Pract Concept. 2023 Jul 01;13(3):
pubmed: 37557130
Mycoses. 1991 Jul-Aug;34(7-8):353-7
pubmed: 1803242
Cureus. 2023 Jun 11;15(6):e40271
pubmed: 37448397
J Fungi (Basel). 2023 Jan 15;9(1):
pubmed: 36675942
J Microbiol Biotechnol. 2023 Mar 28;33(3):319-328
pubmed: 36697229
Med Mycol. 2018 Apr 1;56(suppl_1):S10-S25
pubmed: 29538738
Allergol Int. 2018 Oct;67(4):435-441
pubmed: 30075993
J Invest Dermatol. 1994 Oct;103(4):530-3
pubmed: 7930677
Heredity (Edinb). 2001 Aug;87(Pt 2):215-9
pubmed: 11703512
Skinmed. 2011 Sep-Oct;9(5):283-6
pubmed: 22165042
Front Cell Infect Microbiol. 2020 Apr 09;10:148
pubmed: 32328468
Dermatol Pract Concept. 2021 May 20;11(3):e2021048
pubmed: 34123556
J Dermatolog Treat. 2018 May;29(3):252-255
pubmed: 28984153
Antonie Van Leeuwenhoek. 2003;84(3):185-91
pubmed: 14574113
J Fungi (Basel). 2015 Mar 12;1(1):13-29
pubmed: 29376896
Drugs Context. 2022 Nov 14;11:
pubmed: 36452877
Dermatol Online J. 2020 Mar 15;26(3):
pubmed: 32609438
Dermatology. 2006;212(4):354-60
pubmed: 16707885
Indian J Dermatol. 2013 May;58(3):239
pubmed: 23723483
Molecules. 2019 Jan 24;24(3):
pubmed: 30678374
Antibiot Khimioter. 1989 Oct;34(10):769-73
pubmed: 2619408
Dermatol Pract Concept. 2022 Apr 01;12(2):e2022057
pubmed: 35646451
Clin Microbiol Rev. 2002 Jan;15(1):21-57
pubmed: 11781265
PLoS One. 2013 Jun 07;8(6):e63764
pubmed: 23762233
Photodiagnosis Photodyn Ther. 2020 Jun;30:101743
pubmed: 32198019
J Mycol Med. 2022 Nov;32(4):101301
pubmed: 35700659
J Invest Dermatol. 1953 Oct;21(4):229-31
pubmed: 13096863
Clin Exp Dermatol. 1990 Mar;15(2):95-100
pubmed: 2347114
Int J Dermatol. 1999 Nov;38(11):801-7
pubmed: 10583611
Front Cell Infect Microbiol. 2020 Mar 20;10:112
pubmed: 32266163
Indian Dermatol Online J. 2019 Jul-Aug;10(4):481-485
pubmed: 31334080
J Investig Dermatol Symp Proc. 2005 Dec;10(3):295-7
pubmed: 16382685
Biochem Biophys Res Commun. 2015 Dec 4-11;468(1-2):99-104
pubmed: 26541454
Mycoses. 2018 Aug;61(8):543-548
pubmed: 29601109
Nature. 2013 Jun 20;498(7454):367-70
pubmed: 23698366
Mykosen. 1986 Aug;29(8):378-81
pubmed: 3531847
Front Cell Infect Microbiol. 2021 Jan 26;10:614446
pubmed: 33575223
Arch Dermatol Res. 2017 Apr;309(3):159-167
pubmed: 28180934
Dermatol Nurs. 2008 Oct;20(5):367-70, 377
pubmed: 19051783
BMC Dermatol. 2020 Sep 29;20(1):9
pubmed: 32993612
J Am Acad Dermatol. 2013 Jul;69(1):e19-23
pubmed: 22575159
Med Mycol. 2022 Aug 30;60(8):
pubmed: 35913746
BMJ. 2015 Apr 07;350:h1394
pubmed: 25852089
Diagnostics (Basel). 2023 Mar 04;13(5):
pubmed: 36900129
J Am Acad Dermatol. 1997 Feb;36(2 Pt 1):S3-8
pubmed: 9039198
Int J Dermatol. 1992 Apr;31(4):253-6
pubmed: 1378819
Expert Opin Drug Saf. 2015 Feb;14(2):325-34
pubmed: 25409549
Mycoses. 2017 May;60(5):338-342
pubmed: 28120351
Dermatol Ther. 2020 May;33(3):e13319
pubmed: 32182387
J Dermatolog Treat. 2019 Dec;30(8):760-771
pubmed: 30668185
Arch Dermatol Res. 2007 Dec;299(10):517-20
pubmed: 17960404
Dermatol Pract Concept. 2021 Jul 08;11(3):e2021036
pubmed: 34413999
Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2212533119
pubmed: 36442106
Clin Microbiol Rev. 2011 Apr;24(2):247-80
pubmed: 21482725
Clin Cosmet Investig Dermatol. 2019 Apr 30;12:303-309
pubmed: 31118732
Dermatology. 1997;194 Suppl 1:19-21
pubmed: 9154396
J Clin Microbiol. 2005 Aug;43(8):4147-51
pubmed: 16081962
J Am Acad Dermatol. 1990 Oct;23(4 Pt 2):782-5
pubmed: 2229523
J Invest Dermatol. 2018 May;138(5):1137-1145
pubmed: 29246799
Arch Dermatol Res. 2002 May;294(3):131-4
pubmed: 12029500
Mil Med. 2013 Aug;178(8):904-6
pubmed: 23929053
J Dtsch Dermatol Ges. 2017 Aug;15(8):836-838
pubmed: 28557309
Br J Dermatol. 1992 Feb;126 Suppl 39:61-9
pubmed: 1543676
Dermatol Reports. 2018 Dec 21;11(1):7916
pubmed: 31119026
Acta Derm Venereol. 2015 Jan;95(1):12-9
pubmed: 24556907
Persoonia. 2014 Dec;33:41-7
pubmed: 25737592
Tissue Antigens. 1984 Jan;23(1):47-9
pubmed: 6701887
Lancet. 2004 Sep 25-Oct 1;364(9440):1173-82
pubmed: 15451228
Virulence. 2017 Apr 3;8(3):324-333
pubmed: 27754756
Clin Microbiol Rev. 2012 Jan;25(1):106-41
pubmed: 22232373
Arch Dermatol. 1976 Aug;112(8):1110-2
pubmed: 952528
Allergol Int. 2014 Mar;63(1):83-93
pubmed: 24457815
Mycoses. 2009 Nov;52(6):541-3
pubmed: 19780976
J Dermatolog Treat. 2015 Apr;26(2):143-6
pubmed: 24802530
Dermatol Pract Concept. 2021 Apr 12;11(2):e2021032
pubmed: 33954015
Expert Opin Pharmacother. 2014 Aug;15(12):1707-13
pubmed: 24991691
Dermatol Pract Concept. 2023 Apr 01;13(2):
pubmed: 36795854
Dermatology. 1997;194 Suppl 1:22-4
pubmed: 9154397
Int J Dermatol. 1999 Nov;38(11):863-5
pubmed: 10583623